title: CML--Where do we stand in 2015?
authors: Medizinische Fakultät Mannheim, Universität Heidelberg, Pettenkoferstr. 22, Mannheim, 68169, Germany, R.Hehlmann@urz.uni-heidelberg.de.
authors: Rüdiger
authors: R
authors: Hehlmann
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D035843:Biomedical Research / Q000639:trends; D019317:Evidence-Based Medicine; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors